CRA developed economic analyses to determine damages in a patent infringement case involving a pharmaceutical product used for the treatment of congestive heart failure and skinny labeling by a generic competitor. CRA provided an initial report on economic damages calculating lost profits and reasonable royalties as well as deposition and trial testimony.
IP Literature Watch: November 2024
We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on antitrust & IP, licensing, litigation, innovation, law...